Lobe Sciences Ltd. is a biopharmaceutical company, which engages in the discovery and development of transformative medicines to treat rare diseases. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2012-06-19. The Company, through its wholly owned subsidiaries, Alera Pharma, Inc. and Altemia, Inc., is advancing the development of a patented drug candidate aimed at treating neurological disorders, with an initial focus on chronic cluster headache (Alera). The firm commercializes Altemia MF, a medical food designed to manage deficiencies commonly found in sickle cell disease. Additionally, through Cynaptec Pharmaceuticals, Inc. (Cynaptec), the Company retains an interest in developing Conjugated Psilocin in neurology and psychiatric indications. Conjugated Psilocin is a patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.
LOBEF stock price ended at $0.04 on 星期三, after dropping 20.00%
On the latest trading day Jan 28, 2026, the stock price of LOBEF fell by 20.00%, dropping from $0.05 to $0.04. During the session, the stock saw a volatility of 25.00%, with prices oscillating between a daily low of $0.04 and a high of $0.05. On the latest trading day, the trading volume for LOBEF rose by 39.1K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 39.6K shares were traded, with a market value of approximately $10.7M.